Children and adults with neurofibromatosis type 1 (NF1) are predisposed to developing CNS tumors, including optic pathway gliomas (OPGs), brainstem gliomas (BSGs) and high-grade gliomas. Although current first-line treatments for low-grade gliomas (OPGs and BSGs) may prevent further tumor growth, they rarely result in restoration of the associated visual or neurological deficits. The availability of accurate small-animal models of NF1-associated brain tumors has established tractable experimental platforms for the discovery and evaluation of promising therapeutic agents. On the basis of these preclinical studies, biologically targeted agents are now being evaluated in children with NF1-associated low-grade brain tumors. Collectively, these models have also begun to reveal potential neuroprotective and risk assessment strategies for this brain tumor-prone population.

Original languageEnglish
Pages (from-to)415-423
Number of pages9
JournalExpert Review of Anticancer Therapy
Issue number4
StatePublished - Apr 1 2015


  • RAS
  • brainstem glioma
  • cyclic AMP
  • genetically-engineered mice
  • mTOR
  • microglia
  • neurofibromatosis type 1
  • optic pathway glioma
  • preclinical


Dive into the research topics of 'Improving outcomes for neurofibromatosis 1-associated brain tumors'. Together they form a unique fingerprint.

Cite this